^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

CART22

i
Other names: CART22, CART22-65s
Associations
Company:
University of Pennsylvania
Drug class:
CD22-targeted CAR-T immunotherapy
Related drugs:
Associations
11ms
Co-administration of CART22-65s and huCART19 for B-ALL (clinicaltrials.gov)
P1/2, N=93, Recruiting, Stephan Grupp MD PhD | Trial completion date: Jan 2026 --> Jan 2029 | Trial primary completion date: Jan 2025 --> Jan 2027
Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
CD22 (CD22 Molecule)
|
CD19 expression • CD22 expression
|
CART22 • huCART19
1year
IL-10 Levels Differentially Regulate IFNg Signaling of CART19 and CART22 (ASH 2023)
Serial serum samples from pts enrolled on two clinical trials of the murine CART19 CTL019 (NCT01626495 & NCT02906371) and CART22 (NCT02650414) were examined...All pts who received CART22 had previously received CD19 directed immunotherapy (CART19 N=16, blinatumomab N=1)... Comparing comprehensive serum proteomic profiling between CART19 and CART22 pts we make several novel observations. First, IL-10 levels are significantly higher in CART22 pts at pre-infusion, suggesting that previous immunotherapy has caused an upregulation of this anti-inflammatory cytokine. Second, we show that IL-10 levels have a differential impact on IFNγ levels in CART19 vs CART22 cells.
IO biomarker
|
IFNG (Interferon, gamma) • CD22 (CD22 Molecule) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • IL10 (Interleukin 10)
|
IL10 elevation
|
Blincyto (blinatumomab) • Kymriah (tisagenlecleucel-T) • CART22
almost2years
Co-administration of CART22-65s and huCART19 for B-ALL (clinicaltrials.gov)
P1/2, N=93, Recruiting, Stephan Grupp MD PhD | Not yet recruiting --> Recruiting
Enrollment open • CAR T-Cell Therapy
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule) • CRP (C-reactive protein)
|
CD19 expression
|
CART22 • huCART19
almost2years
Co-administration of CART22-65s and huCART19 for B-ALL (clinicaltrials.gov)
P1/2, N=93, Not yet recruiting, Stephan Grupp MD PhD
New P1/2 trial • CAR T-Cell Therapy
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule) • CRP (C-reactive protein)
|
CD19 expression
|
CART22 • huCART19
2years
CD22-Targeted CAR-Modified T-Cells Safely Induce Remissions in Children and Young Adults with Relapsed, CD19-Negative B-ALL after Treatment with CD19-Targeted CAR T-Cells (ASH 2022)
After fludarabine/cyclophosphamide lymphodepletion, patients (pts) were infused with CART22-65s using a 3-day fractionated dosing scheme with the 2nd/3rd doses held for early signs of cytokine release syndrome (CRS)...Of 17 pts infused (median age, 16 years; range 3-28 years), all had CD19-negative, relapsed disease after prior CD19-directed therapy (CART19, n=16; blinatumomab, n=1); 8 had prior inotuzumab; 9 had prior stem cell transplant (SCT); and 3 had multiple prior SCTs...Other SAEs included: (1) platelet refractoriness and recurrent, severe inflammatory reactions to platelet transfusions in 1 pt that improved with corticosteroids and anakinra; and (2) delayed hemophagocytic lymphohistiocytosis in 1 pt after CART22-65s retreatment that resolved without intervention... CART22-65s induced remissions in 77% of children and young adults with highly refractory, CD19-negative B-ALL, including in 4/5 pts refractory to prior CD22-directed therapy. Manufacturing was successful, and the overall toxicity profile was favorable even in pts with high disease burden. Several uncommon toxicities were observed, but the only grade 3 CRS and neurotoxicity events occurred in the retreatment setting.
Clinical • CAR T-Cell Therapy • IO biomarker
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
cyclophosphamide • Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin) • fludarabine IV • CART22 • Kineret (anakinra)
almost3years
CD22 Redirected Autologous T Cells for ALL (clinicaltrials.gov)
P1, N=15, Recruiting, University of Pennsylvania | Trial completion date: Dec 2022 --> Dec 2037 | Trial primary completion date: Dec 2021 --> Dec 2037
Trial completion date • Trial primary completion date
|
CD22 (CD22 Molecule)
|
CART22
3years
CART22-65s Co-Administered with huCART19 in Adult Patients with Relapsed or Refractory ALL (ASH 2021)
Methods : Adult patients with r/r ALL were co-administered two humanized autologous CAR T cell products, one targeted to CD19 (huCART19) and the other to CD22 (CART22-65s) after fludarabine and cyclophosphamide lymphodepletion... Of 13 treated patients (median age 46 (range 28-71)), two had received prior murine CART19 cells, 8 had prior blinatumomab, 8 had prior inotuzumab and 10 had a prior allogeneic stem cell transplant (SCT)...This syndrome was refractory to IL6 and IL1beta inhibition but ultimately responded to ruxolitinib... Co-administration and adaptive dosing of CART22-65s with huCART19 in adult patients with r/r ALL is feasible and effective. The two different products demonstrated differential expansion and persistence kinetics. Despite prior exposure to CD19- and/or CD22-specific immunotherapies, all evaluable patients achieved CR with uMRD; we continue to monitor CAR T cell persistence and its impact on durability of response.
Clinical
|
IL6 (Interleukin 6) • CD22 (CD22 Molecule) • IL1B (Interleukin 1, beta)
|
CD19 expression
|
Jakafi (ruxolitinib) • cyclophosphamide • Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin) • fludarabine IV • CART22 • huCART19